These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 25149706)

  • 21. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
    Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
    Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumors.
    Gebreyohannes YK; Burton EA; Wozniak A; Matusow B; Habets G; Wellens J; Cornillie J; Lin J; Nespi M; Wu G; Zhang C; Bollag G; Debiec-Rychter M; Sciot R; Schöffski P
    Clin Exp Med; 2019 May; 19(2):201-210. PubMed ID: 30523507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy.
    Wardelmann E; Büttner R; Merkelbach-Bruse S; Schildhaus HU
    Virchows Arch; 2007 Oct; 451(4):743-9. PubMed ID: 17701051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers.
    George S; von Mehren M; Fletcher JA; Sun J; Zhang S; Pritchard JR; Hodgson JG; Kerstein D; Rivera VM; Haluska FG; Heinrich MC
    Clin Cancer Res; 2022 Apr; 28(7):1268-1276. PubMed ID: 35091442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events.
    Huss S; Pasternack H; Ihle MA; Merkelbach-Bruse S; Heitkötter B; Hartmann W; Trautmann M; Gevensleben H; Büttner R; Schildhaus HU; Wardelmann E
    Hum Pathol; 2017 Apr; 62():206-214. PubMed ID: 28159677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.
    Patrikidou A; Domont J; Chabaud S; Ray-Coquard I; Coindre JM; Bui-Nguyen B; Adenis A; Rios M; Bertucci F; Duffaud F; Chevreau C; Cupissol D; Pérol D; Emile JF; Blay JY; Le Cesne A;
    Eur J Cancer; 2016 Jan; 52():173-80. PubMed ID: 26687836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
    Wardelmann E; Merkelbach-Bruse S; Pauls K; Thomas N; Schildhaus HU; Heinicke T; Speidel N; Pietsch T; Buettner R; Pink D; Reichardt P; Hohenberger P
    Clin Cancer Res; 2006 Mar; 12(6):1743-9. PubMed ID: 16551858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer.
    Escudier B; Grünwald V; Ravaud A; Ou YC; Castellano D; Lin CC; Gschwend JE; Harzstark A; Beall S; Pirotta N; Squires M; Shi M; Angevin E
    Clin Cancer Res; 2014 Jun; 20(11):3012-22. PubMed ID: 24691021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.
    Deprimo SE; Bello CL; Smeraglia J; Baum CM; Spinella D; Rini BI; Michaelson MD; Motzer RJ
    J Transl Med; 2007 Jul; 5():32. PubMed ID: 17605814
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated.
    Penzel R; Aulmann S; Moock M; Schwarzbach M; Rieker RJ; Mechtersheimer G
    J Clin Pathol; 2005 Jun; 58(6):634-9. PubMed ID: 15917417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of mutant free circulating tumor DNA in the plasma of patients with gastrointestinal stromal tumor harboring activating mutations of CKIT or PDGFRA.
    Maier J; Lange T; Kerle I; Specht K; Bruegel M; Wickenhauser C; Jost P; Niederwieser D; Peschel C; Duyster J; von Bubnoff N
    Clin Cancer Res; 2013 Sep; 19(17):4854-67. PubMed ID: 23833305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer.
    Lim SM; Chung WY; Nam KH; Kang SW; Lim JY; Kim HG; Shin SH; Sun JM; Kim SG; Kim JH; Kang CW; Kim HR; Cho BC
    Eur J Cancer; 2015 Aug; 51(12):1588-95. PubMed ID: 26070683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KIT overexpression and amplification in gastrointestinal stromal tumors (GISTs).
    Tabone S; Théou N; Wozniak A; Saffroy R; Deville L; Julié C; Callard P; Lavergne-Slove A; Debiec-Rychter M; Lemoine A; Emile JF
    Biochim Biophys Acta; 2005 Jun; 1741(1-2):165-72. PubMed ID: 15869870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
    Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS
    Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gastrointestinal stromal tumors presenting as omental masses--a clinicopathologic analysis of 95 cases.
    Miettinen M; Sobin LH; Lasota J
    Am J Surg Pathol; 2009 Sep; 33(9):1267-75. PubMed ID: 19440146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.
    Lasota J; Miettinen M
    Histopathology; 2008 Sep; 53(3):245-66. PubMed ID: 18312355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative analysis of the BRAF
    Ashida A; Sakaizawa K; Mikoshiba A; Uhara H; Okuyama R
    Int J Clin Oncol; 2016 Oct; 21(5):981-988. PubMed ID: 27041702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The analysis of status and clinical implication of KIT and PDGFRA mutations in gastrointestinal stromal tumor (GIST).
    Du CY; Shi YQ; Zhou Y; Fu H; Zhao G
    J Surg Oncol; 2008 Sep; 98(3):175-8. PubMed ID: 18618605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
    Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
    Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.